Bevacizumab plus capecitabine improves PFS in colorectal cancer
9 June 2010
| by Nicola Garrett
Capecitabine and bevacizumab should be considered a first line therapy option for patients with metastatic colorectal cancer (mCRC), say the Australasian Gastrointestinal Trials Group....
Want to read complete article? Please Sign in or Register.